Results 121 to 130 of about 50,322 (261)

Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review

Journal of Inflammation Research, 2022
Ahmed Mohammed Albakri, Ahmed Hussein Subki, Abdurahman Albeity, Hussein Halabi Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaCorrespondence: Ahmed Hussein Subki; Hussein Halabi, Department of Internal ...
Albakri AM, Subki AH, Albeity A, Halabi H   +3 more
doaj  

Porphyria cutanea tarda, dermatomyositis and non-Hodgkin lymphoma in virus C infection [PDF]

, 2003
Virus C infection has been associated with a broad spectrum of extrahepatic diseases such as essential mixed cryoglobulinemia, membranous glomerulonephritis, vasculitis, rheumatoid arthritis and lupus erythematosus.
Bauza, A. (Ana), España, A. (Agustín), Lloret, P. (Pedro)   +2 more
core  

Palmar erythema: A diagnostic clue of juvenile dermatomyositis [PDF]

, 2020

openalex   +1 more source

Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti‐MDA5 antibody‐positive dermatomyositis related interstitial lung disease [PDF]

, 2023
Yan Li, Xiaoqin Liu, Mi Tian, Ruyi Zou, Yujuan Gao, Mei Huang, Kefeng Zhou, Min Cao, Hourong Cai   +8 more
openalex   +1 more source

Erythematous scaling lesions of the face, dorsal fingers, elbows, and knees together with symmetrical muscle weakness in a child

Clinical Case Reports, 2019
Juvenile dermatomyositis shows characteristic skin lesions. However, this does not rule out co‐occurring other autoimmune diseases, which may be more prominent regarding skin manifestations.
Aleksander Markovic, Volker Schuster, Jan‐Christoph Simon, Manfred Kunz   +3 more
doaj   +1 more source

Rituximab in the treatment of inflammatory myopathies: a review [PDF]

, 2017
Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in refractory myositis did not show a significant difference between the two ...
Fasano, S, Gordon, P, Hajji, R, Isenberg, DA, Loyo, E   +4 more
core  

Functional Index-3: A Valid and Reliable Functional Outcome Assessment Measure in Patients With Dermatomyositis and Polymyositis

, 2020
Floranne C. Ernste, Christopher Chong, Cynthia S. Crowson, Tanaz A. Kermani, Orla Ni Mhuircheartaigh, Helene Alexanderson   +5 more
openalex   +2 more sources

Dermatomyositis: Practical Guidance and Unmet Needs

ImmunoTargets and Therapy
Lydia Cassard,1 Noelle Seraly,2 Maureen Riegert,3 Aditi Patel,4 Anthony P Fernandez5 1Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA; 2Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA ...
Cassard L, Seraly N, Riegert M, Patel A, Fernandez AP   +4 more
doaj  

FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis [PDF]

, 2018
Victoria P. Werth, Emily Z. Hejazi, S.M. Peña, J Háber, Joyce Okawa, Ru Feng, K. Gabre, Josef Concha, C. Cornwall, Nancy Dgetluck, S. Constantine, Barbara White   +11 more
openalex   +1 more source

Polishing the crystal ball: mining multi-omics data in dermatomyositis [PDF]

, 2021
Rochelle Castillo, Alisa N. Femia
openalex   +1 more source